Neuro-Oncology and Brain Tumors

The nervous system getting affected by cancer is one of the severe conditions. The study of cancers of the nervous system is called Neurooncology. Neuro-Oncology is a branch of medicine concerned with the neoplasms of the brain and spinal cord. In the end, it becomes lethal in most cases. It does study, investigation, identification, and treatment for malignant and benign spinal cord and brain tumors.

Neuro-Oncology deals with various tumors like primary tumors of the Central nervous system (CNS) and metastatic tumors of CNS, and their numerous factors causing them at first place. Some worst cancer forms are gliomas of the pons, gliomas of the brainstem, glioblastoma multiforme, and astrocytoma.

The diagnosis of these brain tumors depends heavily on the diagnostic imaging or imaging of the brain. For diagnosis, Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) are mainly used and other tests include Positron Emission Tomography (PET), Myelography and Angiography. The main treatment includes chemotherapy, surgery, radiotherapy, corticosteroids, cancer pain management, and neurosurgical interventions.

Neuro-Oncologists – they are the physician trained to investigate, interpret, diagnose and to treat patients with a brain tumor and tumors of the nervous system.

Sub-tracks:

• Neuro-Oncological disorders
• Spinal metastasis
• Intracranial metastasis
• Skull metastasis
• Psychosocial Advances in Neuro-Oncology

Market Analysis: The global brain tumour medications market is estimated to increase at a compound annual growth rate (CAGR) of 6.3 percent from $1.89 billion in 2020 to $2.01 billion in 2021. In 2020, the market for Brain Tumors in the seven largest markets is expected to be worth USD 2,089.4 million. The United States has the largest market for brain tumours, with a market size of USD 986.0 million in 2020. Italy had the largest market size among the EU5 countries in 2020, with USD 214.4 million, while the United Kingdom had the smallest market size, with USD 129.8 million. In 2020, the Japan Brain Tumors market will be worth USD 256.7 million. This market is expected to increase at a CAGR of 10.4 percent over the forecast period, from USD 2.83 billion in 2021 to USD 5.64 billion in 2028.